Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...

Bain Capital, a global private investment firm, has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma ...

The Japanese chemical company has agreed to sell its pharmaceutical business to Bain Capital for more than $3 billion, in a ...

U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), ...

Bain Capital, an investment firm that has spread its life sciences bets mainly across companies developing novel new medicines, is acquiring Mitsubishi Tanabe Pharma Corporation in a multi-billion ...

Mitsubishi Tanabe Pharma, for over 500 billion yen . This move aligns with Mitsubishi Chemical's strategy to streamline its operations and concentrate on core sectors such as vehicle ...

The deal values Mitsubishi Tanabe Pharma at about 510 billion yen (S$4.53 billion), according to a statement on Friday (Feb 7), which confirmed an earlier report from Bloomberg News. The transaction ...

A deal could value Mitsubishi Tanabe Pharma at more than ¥500 billion yen ($3.3 billion), the people said.

The U.S. investment company said Friday that it will buy Mitsubishi Tanabe Pharma for about 510 billion yen, equivalent to $3.37 billion.

By Anton Bridge and Kane Wu TOKYO (Reuters) -U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), saying it was encouraged by ...